Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) - HC Wainwright issued their FY2029 EPS estimates for Acrivon Therapeutics in a report released on Wednesday, March 26th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings of ($1.25) per share for the year. HC Wainwright currently has a "Buy" rating and a $19.00 target price on the stock. The consensus estimate for Acrivon Therapeutics' current full-year earnings is ($2.49) per share.
Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.09.
Other analysts also recently issued research reports about the stock. KeyCorp assumed coverage on shares of Acrivon Therapeutics in a report on Friday, January 31st. They issued an "overweight" rating for the company. Cantor Fitzgerald reissued an "overweight" rating on shares of Acrivon Therapeutics in a research report on Wednesday, March 26th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $23.17.
Get Our Latest Research Report on Acrivon Therapeutics
Acrivon Therapeutics Stock Down 5.1 %
NASDAQ ACRV traded down $0.12 on Thursday, reaching $2.13. The company had a trading volume of 137,527 shares, compared to its average volume of 95,507. The company's fifty day moving average is $5.35 and its 200 day moving average is $6.50. Acrivon Therapeutics has a 52-week low of $2.06 and a 52-week high of $11.90. The stock has a market capitalization of $66.16 million, a P/E ratio of -0.79 and a beta of 0.85.
Institutional Investors Weigh In On Acrivon Therapeutics
Several large investors have recently modified their holdings of the stock. Wealthedge Investment Advisors LLC purchased a new position in Acrivon Therapeutics in the fourth quarter valued at approximately $65,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Acrivon Therapeutics by 29.7% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 102,784 shares of the company's stock valued at $619,000 after buying an additional 23,535 shares during the last quarter. Corton Capital Inc. bought a new position in shares of Acrivon Therapeutics during the 4th quarter worth $73,000. Acorn Capital Advisors LLC purchased a new stake in Acrivon Therapeutics in the 4th quarter worth about $2,440,000. Finally, Northern Trust Corp lifted its holdings in Acrivon Therapeutics by 11.3% during the fourth quarter. Northern Trust Corp now owns 117,323 shares of the company's stock valued at $706,000 after purchasing an additional 11,925 shares during the last quarter. Hedge funds and other institutional investors own 71.62% of the company's stock.
About Acrivon Therapeutics
(
Get Free Report)
Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Featured Articles
Before you consider Acrivon Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acrivon Therapeutics wasn't on the list.
While Acrivon Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
